SLC2A1 and breast carcinoma: We reported previously that a GLUT1 inhibitor WZB117 displayed a synergistic anticancer effect against MCF-7 and MDA-MB-231 breast cancer cells when combined with a potent Akt inhibitor MK-2206 (Li et al., 2019).